IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1

Journal of Immunology

Volumn 175, Issue 3, 2005, Pages 2018-2025

  Yang, Huan ^a,c   Tüzün, Erdem ^a   Alagappan, Dhivyaa ^a   Yu, Xiang ^a   Scott, Benjamin G ^a   Ischenko, Alexander ^b   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Institute for Highly Pure Biopreparations   (Russian Federation)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG INDUCED DISEASE; IMMUNIZATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; SYMPTOM; T LYMPHOCYTE;

EID: 22644444901     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.3.2018     Document Type: Article

References (43)

1. Drachman, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797-1810.
2. Christadoss, P., M. Poussin, and C. Deng. 2000. Animal models of myasthenia gravis. Clin. Immunol. 94: 75-87.
3. Vincent, A. 2002. Unraveling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2: 797-804.
4. Christadoss, P., J. Lindstrom, S. Munro, and N. Talal. 1985. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J. Neuroimmunol. 8: 29-41.
5. Tüzün, E., B. G. Scott, E. Goluszko, S. Higgs, and P. Christadoss. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171: 3847-3854.
6. Christadoss, P. 1988. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140: 2589-2592.
7. Tüzün, E., B. G. Scott, H. Yang, B. Wu, E. Goiuszko, M. Guigneaux, S. Higgs, and P. Christadoss. 2004. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 172: 5743.
8. Deng, C., E. Goluszko, E. Tüzün, H. Yang, and P. Christadoss. 2002. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169: 1077-1083.
9. Balasa, B., C. Deng, J. Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick. 1997. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186: 385-391.
10. Zhang, G.-X., B.-G. Xiao, X.-F. Bai, P. H. van der Meide, A. Örn, and H. Link. 1999. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:3775-3781.
11. Moiola, L., F. Galbiati, G. Martino, S. Amadio, E. Brambilla, G. Comi, A. Vincent, L. M. Grimaldi, and L. Adorini. 1998. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28: 2487-2497.
12. Jander, S., and G. Stoll. 2002. Increased serum levels of the interferon-γ-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 59: 287-289.
13. Shi, F.-D., H.-B. Wang, H. Li, S. Hong, M. Taniguchi, H. Link, L. Van Kaer, and H.-G. Ljunggren. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1: 245-251.
14. Poussin, M. A., E. Goluszko, J. U. Franco, and P. Christadoss. 2002. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J. Neuroimmunol. 125: 51-58.
15. Matusevicius, D., V. Navikas, W. Palasik, R. Pirskanen, S. Fredrikson, and H. Link. 1996. Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perform mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71: 191-198.
16. Goluszko, E., C. Deng, M. A. Poussin, and P. Christadoss. 2002. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental myasthenia gravis. J. Neuroimmunol. 122: 85-93.
17. Wang, H.-B., H. Li, F. D. Shi, B. J. Chambers, H. Link, and H.-G. Ljunggren. 2000. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int. Immunol. 12: 1381-1388.
18. Zhang, G. X., V. Navikas, and H. Link. 1997. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 20: 543-551.
19. Huang, D., F. D. Shi, R. Giscombe, Y. Zhou, H.-G. Ljunggren, and A. K. Lefvert. 2001. Disruption of the IL-1β gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. Eur. J. Immunol. 31: 225-232.
20. Poussin, M. A., E. Goluszko, T. K. Hughes, S. I. Duchicella, and P. Christadoss. 2000. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111: 152-160.
21. Christadoss, P., and E. Goluszko. 2002. Myasthenia gravis. In Cytokines and Autoimmune Disease. V. K. Kuchroo, D. A. Hafler, and N. Sarvetnick, eds. Humana Press, Totowa, NJ, pp. 373-385.
22. Sciacca, F. L., C. Ferri, F. Veglia, F. Andreetta, R. Mantegazza, F. Cornelio, D. Franciotta, G. Piccolo, V. Cosi, A. P. Batocchi, et al. 2002. IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset. J. Neuroimmunol. 122: 94-99.
23. Huang, D., R. Pirskanen, P. Hjelmstrom, and A. K. Lefvert. 1998. Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis. J. Neuroimmunol. 81: 76-81.
24. Christadoss, P., and E. Goluszko. 2002. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J. Neuroimmunol. 122: 186-190.
25. Arend, W. P. 2002. The balance between IL-1 and IL-1ra in disease. Cytokine Growth Factor Rev. 13: 323-340.
26. Arend, W. P., M. Malyak, C. J. Guthridge, and C. Gabay. 1998. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16: 27-55.
27. Iwakura, Y. 2002. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 13: 341-355.
28. Smith, D. E., R. Hanna, D. Friend, H. Moore, H. Chen, A. M. Farese, T. J. MacVittie, G. D. Virca, and J. E. Sims. 2003. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18: 87-96.
29. Bresnihan, B. 2002. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin. Exp. Rheumatol 20: S32-S34.
30. Hallegua, D. S., and M. H. Weisman. 2002. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann. Rheum. Dis. 61: 960-967.
31. Freeman, B. D., and T. G. Buchman. 2001. Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert Opin. Biol. Ther. 1: 301-308.
32. Badovinac, V., M. Mostarica-Stojkovic, C. A. Dinarello, and S. Stosic-Grujicic. 1998. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J. Neuroimmunol. 85: 87-95.
33. Dayer, J. M. 2002. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin. Exp. Rheumatol. 20: S14-S20.
34. Palmer, G., D. Talabot-Ayer, L. Szalay-Quinodoz, M. Maret, W. P. Arend, and C. Gabay. 2003. Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. Eur. J. Immunol. 33: 434-440.
35. Lindstrom, J., B. Einarson, and S. Tzartos. 2000. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74(Pt. C): 432-460.
36. Wu, B., E. Goluszko, and P. Christadoss. 1997. Experimental autoimmune myasthenia gravis in the mouse. In Current Protocols of Immunology, Vol. 3:15. J. E. Coligan, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, p. 8.1-8.16.
37. Yang, H., E. Goluszko, C. David, D. K. Okita, B. Conti-Fine, T. S. Chan, M. A. Poussin, and P. Christadoss. 2002. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J. Clin. Invest. 109: 1111-1120.
38. Balasa, B., C. Deng, J. Lee, P. Christadoss, and N. Sarvetnick. 1998. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161: 2856-2862.
39. Rowin, J., M. N. Meriggioli, E. Tüzün, S. Leurgans, and P. Christadoss. 2004. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63: 2390-2392.
40. Tüzün, E., M. N. Meriggioli, J. Rowin, H. Yang, and P. Christadoss. 2005. Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. J. Autoimmun. 24: 261-268.
41. Wu, B., C. Deng, E. Goluszko, and P. Christadoss. 1997. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159: 3016-3023.
42. Vernet-der Garabedian, B., J, F. Bach, and E. Morel. 1987. Protective effect of myasthenic immunoglobulins against the lethal toxicity of α bungarotoxin. Clin. Exp. Immunol. 68: 130-137.
43. Kuncl, R. W., D. B. Drachman, R. Adams, and M. Lehar. 1993. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors. J. Pharmacol. Exp. Ther. 267: 582-589.